Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2018

01-05-2018 | Editorial

Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?

Author: Marwan S. Abougergi

Published in: Digestive Diseases and Sciences | Issue 5/2018

Login to get access

Excerpt

Upper gastrointestinal hemorrhage is a frequent gastrointestinal emergency accounting for > 250,000 hospitalizations annually in the USA [1]. Traditionally, upper gastrointestinal hemorrhage has been divided into non-variceal and variceal, due to the significantly different prognosis associated with each category. The last two decades have witnessed major advances in upper gastrointestinal hemorrhage preventive and treatment modalities, including the discovery of Helicobacter pylori, the widespread use of proton pump inhibitors, and the development of novel endoscopic and radiologic hemostatic techniques. Countering these positive developments during the same time period has been the unprecedented widespread use of antiplatelet drugs and anticoagulants, [2] in addition to an epidemic of obesity and opioid abuse, all of which are risk factors for variceal and non-variceal upper gastrointestinal hemorrhage. …
Literature
1.
go back to reference Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc. 2015;81:882–888.CrossRefPubMed Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc. 2015;81:882–888.CrossRefPubMed
2.
go back to reference Brinker AD, Swartz L. Growth in clopidogrel–aspirin combination therapy. Ann Pharmacother. 2006;40:1212–1213.CrossRefPubMed Brinker AD, Swartz L. Growth in clopidogrel–aspirin combination therapy. Ann Pharmacother. 2006;40:1212–1213.CrossRefPubMed
3.
go back to reference Taefi A, Cho WK, Nouraie M. Decreasing trend of upper gastrointestinal bleeding mortality risk over three decades. Dig Dis Sci. 2013;58:2940–2948.CrossRefPubMed Taefi A, Cho WK, Nouraie M. Decreasing trend of upper gastrointestinal bleeding mortality risk over three decades. Dig Dis Sci. 2013;58:2940–2948.CrossRefPubMed
4.
go back to reference Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190.CrossRefPubMed Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190.CrossRefPubMed
7.
go back to reference Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113.CrossRefPubMed Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010;152:101–113.CrossRefPubMed
Metadata
Title
Epidemiology of Upper Gastrointestinal Hemorrhage in the USA: Is the Bleeding Slowing Down?
Author
Marwan S. Abougergi
Publication date
01-05-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-4951-5

Other articles of this Issue 5/2018

Digestive Diseases and Sciences 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.